Back to Directory Dayana Leon Email dayanaleon@westat.com Phone 301-738-8305 Institution Westat Address Westat 1600 Research Boulevard Rockville, MD 20850 USA Request an Update Affiliated Studies IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status In Development IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending
IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status In Development
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Withdrawn
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status Pending